| ANITMICROBIAL | CLCr 50—20 ml/min | CLCr 19—10 ml/min | CLCr <10 ml/min |
|---|--|---|---|
| Acyclovir | 5—15 mg/kg Q12H | 5—15 mg/kg Q24H | 2.5mg/kg Q24H |
| 5—15 mg/kg Q8H^^^ Acyclovir-VZV | No change | 800 mg po Q8—12 H | 5 mg/kg Q24H (VZV) 400—800 mg po Q12H |
| 800 mg po q4 h (5x/day) Ampicillin | No Change | 1—2 gm Q6— 8 H | 1—2 gm Q 8 —12H |
| 2 gm Q6H / 2 gm Q4H~ | | | , |
| Amp/Sulbactam 3 gm Q6H | 3 gm Q8H | 1.5—3 gm Q12H | 1.5 gm Q12H, or 1.5—3 gm Q24H |
| Amox/clavulanate | No Change | 875/125 mg Q24H | 500/125 mg Q24 |
| 875/125 mg Q12H Aztreonam | No Change | 1—2 gm Load then 0.5—1 gm Q8H | 1—2 gm Load then 125—500 mg Q8 H |
| 1—2 gm Q6—8H Cefazolin | 1 gm Q8 | 1—2 gm Q12H | 1—2 gm Q24H |
| 2 gm Q8H~ | - | | |
| Cefepime 1—2 gm Q12H / 2g Q8H* | 1 gm Q12H / 2 gm Q12H* | 1 gm Q24H (if MIC ≤ 2) / 1 gm Q12H* otherwise | 500 mg Q24H / 1 gm Q24H* |
| Cefixime 400 mg Q24H or 200 mg Q12H | No Change | 300 mg Q24H | 200 mg Q24H |
| Cefotetan | No Change | 1—2 gm Q24H | 1—2 gm Load then 1 mg Q 48 (or 500 mg Q12) |
| 1—2 gm Q12H / ~ Cefoxitin | 1—2 gm Q8H | 1—2 gm Q12H | 0.5—1 gm Q12—24H |
| 1—2 gm Q6H / 2 gm Q4H~ Ceftaroline fosamil | 400mg Q12H | 300mg Q12H | 200mg Q12H |
| 600mg Q12H Ceftazidime | 1 gm Q12H | 1 gm Q24H | 0.5 gm Q24H |
| 1—2 gm Q8H Ceftizoxime | 1 gm Q12H | 0.5—1 gm Q12H | 0.5—1 gm Q24H |
| 1—2 gm Q8H | ŭ . | <u> </u> | |
| Ceftriaxone 1—2 gm Q12—24H | No Change | No Change | No Change, consider 2 gm Max/d if liver liver + renal |
| Cefuroxime | No Change | 0.75 gm Q12H | 0.75 gm Q24H |
| 0.75—1.5 gm Q8H Cephalexin | No Change | 250—500 mg po Q8—12 H | 250—500 mg po Q 12—24H |
| 250—500 mg po Q6H Cidofovir | Not Recommended | Not Recommended | Not Recommended |
| 5 mg/kg Q Week x2 (Induction) | | | |
| Ciprofloxacin 400 mg Q8—12H | No Change | 400 mg IV Q18H | 400 mg IV Q24H (Q1820?) |
| 500—750 mg po Q 12 H Clarithromycin | 500 mg po Q12H | 500 mg po Q12H | 500 mg po Q18H |
| 250—500 mg po Q12H OR | No Change | 250 mg po Q 12H | 250—500 mg q 24 |
| 1 gm po Q24H of XL Colistin (colistin base activity in mg) | Daily dose CBA (mg) = $(C_{ss,avg})(1.5*CrCL+30)$ | Daily dose CBA (mg) = $(C_{ss,avg})(1.5*CrCL+30)$ | Daily dose CBA (mg) = $(C_{ss,avg})(1.5*CrCL+30)$ |
| load CBA (mg) = (C _{ss,avg})*2*(weight in kg) Colistin (alternate) | Dose q12H. Start 24H after load 4.5 MU/day divided q12H | Dose q12H. Start 24H after load 4.5 MU q48H | Dose q12H. Start 24H after load 4.5 MU q48H |
| load 9 MU, then 24H after load start 4.5 MU q12H | • | • | |
| Ertapenem 1gm Q24H | 500 mg Q24H Clcr < 30 | 500 mg Q24H | 500 mg Q24H |
| Erythromycin 0.5—1 gm Q6H | No Change | No Change | 0.5 gm Q6H |
| Ethambutol (E) | No Change | 15—25 mg/kg Q 36 | 15—25 mg/kg Q 48 |
| 15—25 mg/kg Q day Ethionamide | | | |
| 0.5—1 gm Q24H Fluconazole | No Change 200—400 mg Q 24 | No Change 200 mg q 24 | No Change 100—200 mg Q24H |
| 12 mg/kg IV load on day one, 400 mg Q 24H | <u> </u> | 200 mg q 24 | 100—200 mg Q2411 |
| Foscarnet~~ 60 mg/kg Q8H / 90 mg/kg Q12H (I) | Complicated | | |
| 90 mg/kg Q24H (M) Flucytosine | 25 mg/kg Q12H | 25 mg/kg mg/kg Q24H | 25 mg/kg Q24—48H (adjust using Cp) |
| 25—37.5 mg/kg Q 6H | | | |
| Ganciclovir (IV) 5 mg/kg Q12H induction (I) | 50—70=> 2.5 mg/kg Q12(I) 2.5 mg/kg Q24(M) 20—50=>2.5 mg/kg Q24H (I) 1.25 mg/kg Q24H (M) | 1.25 mg/kg Q24H (I) 0.625 mg/kg Q24H (M) | 1.25 mg/kg TIW (I) 0.625 mg/kg TIW (M) |
| 5 mg/kg Q24H maintanence (M) Ganciclovir (PO) maintenance | 50—70=> 1000 mg Q12H | 10—25=> 500 mg Q24H | 500 mg TIW |
| 1000 mg Q8H | 25—50=> 1000 mg Q24H | | |
| Gatifloxacin 400 mg Q24H | < 40—400 mg load then 200 mg Q24H | 400 mg load then 200 mg Q24H | 400 mg load then 200 mg Q24H |
| Imipenem 0.5 gm Q6H | 500 mg Q8 OR 250 mg Q6H 20—40=> 250 mg Q6—8H | 0.25—0.5 gm Q8—12H | 0.25 gm Q12H |
| Isoniazid (H) | No Change | No Change | 150 mg in slow acetylators |
| 300 mg po q 24 Itraconazole | No Change | No Change (IV not recommended Cr Cl < 30 | IV not recommended Cr Cl < 30 (cyclodextrin) |
| 200 mg Q12H PO OR IV Q12H x 4 doses then Q24H | | (cyclodextrin)) | (yeldusum) |
| Levofloxacin | 500—750 mg x1, then 250—375 mg Q24H or 750 | 500—750 mg x1, then 250 mg Q24H | 500—750 mg x1, then 250—500 mg Q48H |
| 500—750 mg Q24H Linezolid | mg Q48H No Change | No Change | No Change |
| 600 mg Q12H + pyrimidine Meropenem | 1 gm Q8—12H | 1 gm Q12H | 0.5 Q24H |
| 1—2 gm Q8—12H / 2 gm Q8H (meningitis)~ | - | | - |
| Penicillin G 1—4 MU Q4H | 40—60 =1—2 MU Q4 20—40 =1—2 MU Q6 | 1 MU Q6 | 1 MU Q6—8H |
| Pentamidine 4 mg/kg/d Q24H | 4 mg/kg Q24 | 4 mg/kg Q36H | 4 mg/kg Q48H |
| Piperacillin | 4 gm Q6H | 3—4 gm Q8H | 3 gm Q8H or 3—4 gm Q12 |
| 3—4 gm Q 4 H Pip/Tazo | 2.25—3.375 gm Q6H or 4.5 gm Q8 H | 3.375 gm Q8H or 4.5 gm Q12 | 2.25 gm Q8H |
| 3.375—4.5 gm Q6H / Pseudomonas—3.375 gm Q4H Quinine | No Change | 7.5—10 mg/kg Q12H | 7.5—10 mg/kg Q24H |
| 7.5—10 mg/kg Q8H | 110 Ghange | Metabolic Cl; inc binding to AAP; 3OH | Metabolic Cl; inc binding to AAP; 3 OH accumulates |
| (650 mg po Q8H) Quinupristin/Dalfopristin | No Change | accumulates—dec dose by 1/3 after 3 day No Change | —dec dose by ½ after 3 days No Change |
| 7.5 mg/kg Q8—12H Ticarcillin/Clavulanate | 2 gm Q4H OR | 2 gm Q8H OR | 2 gm Q12H |
| 3.1 gm Q4—6H | 3.1 gm Q6H | 3.1 gm Q12H | |
| Tigecycline 100 mg x1, then 50 mg Q12H | No Change | No Change | No Change |
| Trimethoprim/Sulfa ** | < 30 => 7.5 mg TMP/kg/d divided Q12H | 5 mg TMP/kg/d Q24H | 3 mg TMP/kg/d Q24H |
| 10 mg TMP/kg/d divided Q8H Trimetrexate | < 30 => PCP 12 mg TMP/kg/d divided Q12H 100% | PCP 7.5 mg/kg TMP Q24H 50-100% | PCP 5—7.5 mg/kg TMP Q 24 No Data; ? avoid |
| 1.2 mg/kg Q24H/ 45 mg/m2 Q24H +Leucovorin Valacyclovir | No Change | 0.5—1 gm Q12—24H | 500 mg Q24H |
| · | 1 Smange | | |

| ANITMICROBIAL | CLCr 50—20 ml/min | CLCr 19—10 ml/min | CLCr <10 ml/min |
|---|--|--|--|
| variable | | | |
| Valganciclovir – Induction 900 mg BID x 3 wks | Normal to ¾ Dose | ½ Dose | 450 mg Q48H x3 wks, then 450 mg BIW |
| Valganciclovir – Maintenance 900 mg Q24H | 40—59=> 450 mg Q24H 25—39=> 450 mg Q48H | 10—24=> 450 BIW | Use ganciclovir PO dosing for CLCr < 10 |
| Vancomycin 1—1.5 gm Q12H (based on TBW, 15—25 mg/kg) | 40—60=> 15 mg/kg Q24H 20—40=> 15 mg/kg load then 7.5 mg/kg Q24H | 15 mg/kg Q48—72H | 15 mg/kg Q4—7d |
| Voriconazole 4—6 mg/kg Q12H (6 mg/kg load) | No Change (IV NOT recommended for CLcr < 50, cyclodextran) | No Change (IV NOT recommended for CLcr < 50, cyclodextran) | No Change (IV NOT recommended for CLcr < 50, cyclodextran) |

The following drugs do NOT need dosage adjustment in renal failure: amphotericin B (any formulation), atovaquone, azithromycin, caspofungin, chloramphenicol (increased bioavailability of chloramphenicol from succinate ester, target 5—20µg/mL), clindamycin, clofazamine dapsone, dicloxacillin, dirithromycin, doxycycline, linezolid, mefloquine, metronidazole, micafungin, miconazole, minocycline, moxifloxacin, nafcillin, oxacillin, primaquine, pyrimethamine, quinupristin/dalfopristin, rifampin, rifabutin, rifapentine, tigecycline

*Neutropenic Dosing. Pip/tazo 3.375 gm Q4H better than continuous infusion (CI) of 13.5 gm (PMID: 16029947). Cefepime 4 gm CI > 1 gm Q8H (2 gm Q8H not assessed, use for CNS & ESBL with < 16 mg/L)

**TMP/SMX listed dosing is for GNR infections other than Stenotrophomonas. Pneumocystis treatment dose is 15 mg TMP/kg/d divided Q6-8H. Stenotrophomonas infection dose is 15-20 mg TMP/kg/d divided Q6H. ADosages are not necessarily appropriate for Endocarditis.

- ^Dosages given are for parenteral therapy unless otherwise specified.
 ^APOosages given are for parenteral therapy unless otherwise specified.
 APOosages given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE given are for parenteral therapy unless otherwise specified.
 APOOSAGE give

- Colistin dosing as "colistin base activity" (CBA) in mg rather than international units. For colistin base 1mg = 30,000 IU. CMS 1mg = 12,500 IU. C_{ss,avg} = target blood level [AAC;55:3284, doi:10.1128/AAC.01733-10] Colistin dosing based on prior data. No PK evaluation, but validated in [CID;54:1720. 2012]

The following drugs may require dosage adjustment in hepatic failure: aztreonam (20—25% reduction +/-), carbenicillin (2g/d max ren+hep), caspofungin (35 mg Q24H moderate disease), cefoperazone (max 4g/d or monitor lvl, 2g/d ren+hep), ceftriaxone (2g/d ren+hep), chloramphenicol (target 5—20µg/mL), clindamycin (+/- if severe), itraconazole (caution, 2-fold increased T½), metronidazole (+/-, target peak 10—20 µg/mL), mezlocillin (dec 50%), nafcillin (+/- if ren+hep), rimantidine (max 100mg/d), ticarcillin (2g/d if ren+hep), tigecycline (100mg load, then 25mg q12H), voriconazole (6mg/kg Q12H x2, then 2 mg/kg Q12H).

 $\frac{Intraperitoneal\ Dosing.}{Ampicillin}.\ Dose\ per\ each\ 2\ liter\ exchange,\ IP\ unless\ otherwise\ noted.}{Ampicillin}$ load 1 gm, maintenance 500 mg load 1 gm, maintenance 500 mg Aztreonam Cefamandole Cefazolin load 1 gm, maintenance 250-500 mg Cefepime load 1 gm, maintenance 250 mg load 1 gm, maintenance 200 mg load 1 gm, maintenance 250—500 mg Cefoxitin Ceftriaxone

Ciprofloxacin Clindamycin load 0.5 gm PO, then maintenance 50 mg IP load 300 mg, maintenance 150 mg Colistin

2mg/kg/d 150 mg QOD Fluconazole


Vancomycin

Flucytosine load 2 gm PO, then maintenance 1 gm PO QD load 2 mg/kg, maintenance 8-12 mg Gentamicin Nafcillin load 250 mg(?), maintenance 125 mg load 1 gm, maintenance 200 mg Imipenem Piperacillin

load 4 gm IV, then maintenance 500 mg 2 gm (30 mg/kg) Q5—7 days

| ANTIMICROBIAL | INTRATHECAL DOSING | |
|-----------------------|---------------------|--|
| Amikacin | 5—7.5 mg Q24H | |
| Colistin | 3.2—10 (20) mg Q24H | |
| Gentamicin/Tobramycin | 4—8 mg Q24H | |
| Vancomycin | 5—20 mg Q24H | |

| Aminoglycoside Dosing CVVH/D/DF | Maintenance Dosage | |
|-------------------------------------|--------------------|--|
| Gentamicin / Tobramycin 3mg/kg load | 2 mg/kg Q24—48H | |
| Amikacin 10 mg/kg load | 7.5 mg/kg Q24—48H | |



| ANITMICROBIAL | HEMODIALYSIS (HD) DOSING | CVVH DOSING | CAVHD / CVVHD / CVVHDF DOSE | CAPD DOSING |
|----------------------------|---|--|---|-------------------|
| Acvclovir | Supplement 2.5mg/kg AD | 5—7.5 mg/kg Q24H | 5—7.5 mg/kg Q24H | Dose for CLCr <10 |
| Aminoglycosides | ½ Full Dose AD & Follow Levels | 3 7.5 mg/ng Q2 111 | Follow Levels | Follow Levels |
| Ampicillin | Dose AD | | Dose for CLCr 20—50 | 250 mg Q12H |
| Ampicillin/Sulbactam | Dose AD | 3 gm Q12H | 3 gm Q8H | 1.5-3 gm Q24H |
| Amoxicillin/clavulanate | Dose AD | 5 giii Q1211 | Dose for CLCr 20—50 | 250/125 mg Q12H |
| Aztreonam | Supplement 0.5 gm AD | 1—2 gm Q12H | 2 gm Q12H or Dose for CLCr 20—50 | Dose for CLCr <10 |
| Cefazolin | Dose AD or Supplement with 1 gm AD | 1—2 gm Q12H | 2 gm Q12H or Dose for CLCr 20—50 | 0.5 gm Q12H |
| Cefepime | 2 gm load, then 0.5 gm Q24H; 2 gm AD supplement | | 2 gm Q12H | Dose for CLCr <10 |
| Cefixime | Supplement 300 mg AD | 1 2 gm Q1211 | No Data | Dose for CLCr <10 |
| Cefotetan | Supplement 1 gm AD | | 0.75 gm Q12H | Dose for CLCr <10 |
| Cefoxitin | Dose AD or Supplement with 1 gm AD | | Dose for CLCr 20—50 | 1 gm Q24H |
| Ceftazidime | Supplement 1 gm AD | 1—2 gm Q12H | Dose for CLCr 20—50 | 0.5 gm Q24H |
| Ceftizoxime | Supplement 1 gm AD | 1—2 giii Q1211 | Dose for CLCr 20—50 | 0.5-1 gm Q24H |
| Ceftriaxone | No Change | No Change | No Change | No Change |
| Cefuroxime | Dose AD | No Change | 1 gm Q12H | Dose for CLCr <10 |
| Cidofovir | No Data | | Avoid Use | No Data |
| Ciprofloxacin | Dose for CLCr <10 | 200 mg Q12H | 200—400 mg Q12H | Dose for CLCr <10 |
| | Dose AD | 200 liig Q12H | Dose for CLCr <10 | |
| Clarithromycin Colistin | C _{ss,avg} each 1mg/L = 30 mg/day +30% on HD day | C _{ss.avg} each 1mg/L = 192 mg/day divided q8—12H | C _{ssave} each 1mg/L = 192 mg/day divided q8—12H | Dose for CLCr <10 |
| | | | | |
| Daptomycin | 4—6 mg/kg Q48H | 4—6 mg/kg Q48H | 4—8 mg Q48H | 4 |
| Ertapenem | 500mg Q24H, 150 mg AD supplement | | N. Cl | 1 gm Q24H |
| Erythromycin | No Change | | No Change | No Change |
| Ethambutol | 25 mg/kg 4H before HD 3x/week | | Dose for CLCr 20—50 | Dose for CLCr <10 |
| Ethionamide | No Change | | No Change | No Change |
| Famciclovir | Dose AD | 200 4004 00 477 | Dose for CLCr 20—50 | No Data |
| Fluconazole | Dose AD | 200—400* mg Q24H | 200—800* mg Q24H | <u> </u> |
| Foscarnet | Dose AD | | Dose for CLCr 20—50 | Dose for CLCr <10 |
| Flucytosine | Dose AD; usual load, then follow levels | | Dose for CLCr 20—50 | 0.5—1 gm Q24H |
| Ganciclovir | Dose AD | | Dose for CLCr 20—50 | Dose for CLCr <10 |
| Gatifloxacin | Dose AD | | Dose for CLCr 20—50 | Dose for CLCr <10 |
| Imipenem | Dose AD/ Not Recommended | 250 mg Q6H or 500 mg Q8H | 500 mg Q8—6H | Dose for CLCr <10 |
| Itraconazole | Dose for CLCr <10 | | 100 mg Q12—24H | 100 mg Q12—24H |
| Levofloxacin | | 500 mg x1, then 250 mg Q24H | 500 mg x1, then 250 mg Q24H | |
| Linezolid | Supplement 200 mg AD | No Change | No Change | No Change |
| Meropenem | Dose AD | 1 gm Q12H or Dose for CLCr 20—50 | 1 gm Q12H or Dose for CLCr 20—50 | Dose for CLCr <10 |
| Metronidazole | Dose AD | | Dose for CLCr 20—50 | Dose for CLCr <10 |
| Mezlocillin | Supplement 3—4 gm AD | | Dose for CLCr 20—50 | 3 gm Q12H |
| Penicillin G | Supplement 0.5 MU AD | | Dose for CLCr 20—50 | Dose for CLCr <10 |
| Pentamidine | No Dosage Adjustment | | | |
| Piperacillin | Supplement 1 gm AD | | Dose for CLCr 20—50 | Dose for CLCr <10 |
| Pip/Tazo | Supplement 1/3 Dose AD | 2.25 gm Q6H | 2.25—3.375 gm Q6H or Dose for CLCr 20—50 | Dose for CLCr <10 |
| Quinine | Dose AD | | Dose for CLCr 20—50 | Dose for CLCr <10 |
| Quinupristin/Dalfopristin | No Dosage Adjustment | | | |
| Ticarcillin/Clavulanate | Supplement 3.1 gm AD | 2 gm Q6—8H | 3.1 gm Q6H or Dose for CLCr 20—50 | Dose for CLCr <10 |
| Trimethoprim/Sulfa ** | Dose AD | | No Data | 0.16/0.8 gm Q48H |
| Trimetrexate | No Data | | No Data | No Data |
| Vancomycin | Dose for CLCr <10 | 15-25 mg/kg load, 1 gm Q48H, check levels | 15—25 mg/kg load, 1 gm Q24H, check levels | Dose for CLCr <10 |
| Voriconazole | IV Not recommended, PO usual dose | 6 mg/kg Q12H x2, load, then 4 mg/kg PO Q12H | 6 mg/kg Q12H x2, load, then 4 mg/kg PO Q12H | Dose for HD |

^{*}lower dose only if MIC ≤ 8 mg/L and not C. krusei or C. glabrata

JUNE 2002 ORIGINAL [A. Gregson]; JUNE/AUGUST 2006 Slight modifications (included updates from CID;41:1159—66, CID;40:1333—41, PMID: 12760858) [A. Gregson]; FEBRUARY 2007 (minor mod) [A. ion]; JANUARY 2008 (minor mod) [A. Gregson]; MARCH 2008 (updated colistin dosing RF & IT from G&G 4th Ed. 1970 p1290—1) [A. Gregson]; MARCH 2011 [A. Gregson]; March—May 2012 [A. Gregson] This document is licensed under the Attribution-NonCommercial-ShareAlike 3.0 United States license, available at http://creativecommons.org/licenses/by-nc-sa/3.0/us/.